RecruitingRecruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591 · GT Medical Technologies, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
About this study
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows:
* A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B.
* A Perioperative/Operative Phase where patients will undergo tumor resection (Arm A) or tumor resection plus GammaTile implantation (Arm B).
* An EBRT Prior to Start Period. This occurs within 10 business days prior to EBRT and Concurrent TMZ Phase.
* An EBRT and Concurrent TMZ Phase, which will begin 30 ±10 days post-surgery. EBRT (30 fractions) and TMZ will be administered up to 5 days a week for 6 weeks in Arm A, and EBRT (20 fractions) and TMZ will be administered for up to 5 days a week for 4 weeks in Arm B. TMZ will be administered at a dose of 75 mg/m2/day orally for each Arm.
* An Adjuvant TMZ Phase, which begins 28 ±7 days following the EBRT and Concurrent TMZ Phase, and is comprised of six 28-day cycles. TMZ (150-200 mg/m2/day orally) will be administered for the first 5 days of each 28-day cycle for each Arm. Tumor treating fields are allowed but are not mandated during this phase. Up to 6 additional cycles (for a total of 12) can be completed at the discretion of the Investigator.
* An Early Discontinuation/Follow-Up Phase will occur 28 ±7 days after completion of Cycle 6 of the Adjuvant TMZ Phase, regardless of the total number of cycles completed or any delays in cycle start. If fewer than six cycles are completed, the first follow-up assessment will occur 28 ±7 days after the last administered dose of adjuvant TMZ. If patient has a qualifying event requiring entrance to Early Discontinuation Phase, the first follow-up assessment will occur as soon as feasible, but within 28 days.
For any unscheduled visits, data collected should be documented in the case report form (CRF) and must include, but are not limited to, safety evaluations, survival status, and disease status.
Eligibility criteria
Major Criteria Includes the Following:
Inclusion Criteria
* Patients must be ≥18 years of age.
* Have radiographic suspicion of newly diagnosed glioblastoma (GBM).
o If final pathology reports IDH mutant glioma, then the patients found to have an IDH mutation will be followed for safety and QoL measures but will not be included in the primary and secondary comparative survival and efficacy analyses.
* Are medically and surgically appropriate for resection.
* Have an estimated Karnofsky Performance Scale (KPS) score of ≥70.
* Are able to receive standard of care treatment.
Exclusion Criteria
* A previous biopsy diagnosis other than IDH wild-type GBM.
* Have contraindications to TMZ, magnetic resonance imaging, gadolinium, or non-contrast computed tomography.
* Have multi-focal enhancing tumors that cannot be encompassed in one operative field.
Study design
Enrollment target: 766 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-12-10
Estimated completion: 2031-12
Last updated: 2026-11-09
Interventions
Device: GammaTile®Radiation: External Beam Radiation TherapyDrug: Temozolomide
Primary outcomes
- • Overall Survival (Days from surgery to death.)
Sponsor
GT Medical Technologies, Inc. · industry
Contacts & investigators
ContactKimberly Johnson · contact · kjohnson@gammatile.com · (833)662-0044
All locations (22)
HonorHealth Scottsdale Osborn Medical CenterRecruiting
Scottsdale, Arizona, United States
Keck Medicine of USCRecruiting
Los Angeles, California, United States
Cedars Sinai Medical CenterRecruiting
Los Angeles, California, United States
Sutter HealthRecruiting
San Francisco, California, United States
University of California San FransicoRecruiting
San Francisco, California, United States
Advent Health - ColoradoRecruiting
Littleton, Colorado, United States
Advent HealthRecruiting
Orlando, Florida, United States
Emory Winship Cancer InstituteRecruiting
Atlanta, Georgia, United States
Rush University Medical CenterRecruiting
Chicago, Illinois, United States
Norton Cancer Institute - BrownsboroRecruiting
Louisville, Kentucky, United States
Johns Hopkins UniversityRecruiting
Baltimore, Maryland, United States
University of MissouriRecruiting
Columbia, Missouri, United States
Dartmouth Hitchcock Medical CenterRecruiting
Lebanon, New Hampshire, United States
Jersey Shore University Medical Center | HackensackRecruiting
Neptune City, New Jersey, United States
Westchester Medical CenterRecruiting
Valhalla, New York, United States
East Carolina UniversityRecruiting
Greenville, North Carolina, United States
The Ohio State UniversityRecruiting
Columbus, Ohio, United States
Allegheny Health NetworkRecruiting
Pittsburgh, Pennsylvania, United States
Brown University HealthRecruiting
Providence, Rhode Island, United States
Medical University of South CarolinaRecruiting
Charleston, South Carolina, United States
Houston MethodistRecruiting
Houston, Texas, United States
Inova Schar Cancer InstituteRecruiting
Fairfax, Virginia, United States